Patient Centered Quality Care for Life Act

Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, Repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R.2941 and S.3493; H.R.3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; H.R.4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; the implementation of P.L. 111-148, the Patient Proection and Affordable Care Act of 2010; S.1064, the Sun Act; S.965, the Family Act; H.R.2954, Health Equity and Accountability Act of 2011; and H.R.2077, the MLR Repeal Act; H.R.2245 and S.296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S.3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, Amendment relating to S.1813, the Moving Ahead for Progress in the 21st Century Act, and H.R.4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Issues relating to global health including S.2515, the Clean Cookstoves Support Act of 2012; H.R.6155 & S.3047, the Palliative Care and Hospice Education & Training Act; and H.R.6157, the Patient Centered Quality of Care Act.

Client expense: $620,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office

Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. H.R. 6157, Patient Centered Quality Care for Life Act of 2012

Client expense: $25,001 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE